V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160015306 | 160017947 | 1.72 | 108 | Palliative (P) | 2017-04-11 | 2017-05-10 | IPM | 02 | null | CARBOPLATIN + LIPOSOMAL DOX | 100439448 |
| 160015309 | 160017949 | 1.82 | 30.8 | null | 2021-05-06 | 2021-10-07 | BEVACIZUMAB + CARBO + PACLITAXEL | null | null | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 101681748 |
| 160015339 | 160017950 | 0 | 11.6 | Palliative (P) | 2019-01-27 | 2019-02-25 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | null | GEMCITABINE | 100091203 |
| 160015341 | 160017951 | 1.68 | 66.3 | Adjuvant (A) | null | 2017-08-19 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | N | STS RHABDO VIT0910 VINC IRINO TEMOZ | 100707005 |
| 160015343 | 160017952 | 0 | 0 | Palliative (P) | 2020-10-15 | 2020-10-23 | EW EuroEwing 2012 Arm B IE | null | null | GEMCITABINE | 100568238 |
| 160015363 | 160017953 | 1.63 | 34 | Palliative (P) | null | null | PROMISE-MESO TRIAL | 02 | N | MELPHALAN | 101490726 |
| 160015365 | 160017954 | 1.11 | 86 | Palliative (P) | 2022-01-11 | 2022-01-30 | IPILIMUMAB + NIVOLUMAB | 02 | N | IPILIMUMAB + NIVOLUMAB | 100493687 |
| 160015368 | 160017955 | 1.74 | 31 | null | 2022-02-06 | 2022-02-17 | Irinotecan + Temozolomide | 02 | null | PEMBROLIZUMAB | 101455843 |
| 160015369 | 160017956 | 1.73 | 48.1 | Adjuvant (A) | 2020-07-22 | 2020-07-22 | Dacarbazine | 02 | N | STS RHABDO VIT0910 VINC IRINO TEMOZ | 100636134 |
| 160015378 | 160017957 | 1.7 | 52.4 | null | null | 2018-10-01 | Bortezomib + Daratumumab | 02 | null | PALBOCICLIB | 100356244 |
| 160015392 | 160017958 | 1.84 | 83 | Palliative (P) | 2018-05-01 | 2018-05-11 | null | 01 | N | DOXORUBICIN + IFOSFAMIDE | 101583893 |
| 160015394 | 160017959 | 1.61 | 9.7 | null | 2021-04-01 | 2021-04-07 | Trial Unspecified | null | null | GEMCITABINE | 101565022 |
| 160015408 | 160017960 | 1.92 | 61.9 | Disease modification (D) | 2019-12-14 | 2019-12-28 | FLUOROURACIL + IRINOTECAN | 02 | N | GEMCITABINE | 100543165 |
| 160015412 | 160017961 | 1.93 | 20 | Palliative (P) | 2017-08-22 | 2017-09-23 | Etoposide oral | 02 | N | ICON8B TRIAL | 100477131 |
| 160015420 | 160017962 | 1.83 | 81 | Curative (C) | 2018-12-01 | 2019-08-20 | ETOP 13-18 BEAT-meso Trial | 02 | N | NOT MATCHED | 101071981 |
| 160015422 | 160017963 | 1.86 | 71.6 | null | 2021-01-09 | 2021-01-27 | null | 02 | N | ETOPOSIDE + IFOSFAMIDE | 100398937 |
| 160015433 | 160017964 | 1.49 | 98.1 | null | 2018-05-20 | 2018-05-24 | Pemetrexed | 02 | N | ATOMIC-MESO TRIAL | 101549250 |
| 160015437 | 160017965 | 0 | 55.55 | null | 2018-04-02 | 2018-04-05 | IVA | null | null | NB HRNBL | 101573225 |
| 160015442 | 160017966 | 1.85 | 74.5 | Palliative (P) | 2019-11-02 | 2019-12-03 | Rucaparib | 02 | N | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 100059880 |
| 160015449 | 160017967 | 1.14 | 118 | null | null | null | NB BEACON Temozolomide Topotecan | 02 | null | BEVACIZUMAB + CARBO + PACLITAXEL | 101614057 |
| 160015451 | 160017968 | 1.5 | 76.6 | null | 2018-02-01 | 2018-02-17 | EpSSG NRSTS 2005 | null | null | RMS 2005 TRIAL | 100134593 |
| 160015470 | 160017969 | 1.78 | 78.2 | null | 2017-03-06 | 2017-03-16 | BEP 5 Day | 01 | null | NB HRNBL-1 COJEC IND COURSE B | 100866674 |
| 160015473 | 160017970 | 1.4 | 39.1 | Palliative (P) | 2020-07-31 | 2020-07-31 | Irinotecan + Temozolomide | N | N | CYCLOPHOSPHAMIDE + VINCRISTINE | 101665415 |
| 160015478 | 160017971 | null | 86.2 | null | 2017-12-31 | 2018-01-03 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | CONFIRM TRIAL | 101286188 |
| 160015493 | 160017972 | 1.65 | 93.9 | Curative (C) | 2017-04-06 | 2017-09-06 | EW EuroEwing 2012 Arm B VC | 02 | N | GEMCITABINE | 100142276 |
| 160015508 | 160017973 | 1.59 | 74.9 | null | 2022-05-01 | 2022-05-02 | NB HRNBL-1 ch14.18/CHO only (trial) | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101711066 |
| 160015513 | 160017974 | 1.86 | 92.9 | null | 2021-03-17 | 2021-03-26 | STS Rhabdo VIT0910 Vinc Irino Temoz | 02 | null | IRINOTECAN + CISPLATIN + MITOMYCIN | 101828378 |
| 160015524 | 160017976 | 1.59 | 73.8 | null | 2017-12-09 | 2017-12-22 | Cyclophosphamide oral | 02 | null | CONFIRM TRIAL | 100170197 |
| 160015526 | 160017977 | 1.72 | 104 | null | 2018-03-20 | 2018-03-21 | IPILIMUMAB + NIVOLUMAB | 02 | null | IMATINIB | 100474742 |
| 160015528 | 160017978 | 1.69 | 62.6 | Palliative (P) | 2016-06-03 | 2016-06-03 | Lenalidomide 25mg (Cycle 1 to 25) | 02 | N | DOCETAXEL + TRASTUZUMAB | 101653921 |
| 160015535 | 160017979 | 1.81 | 10.8 | null | 2018-08-10 | 2018-08-10 | STS Rhabdo VIT0910 Vinc Irinotecan | null | null | ACALABRUTINIB | 101424685 |
| 160015541 | 160017980 | 0 | 101.9 | null | 2017-05-26 | 2018-03-23 | null | 02 | null | NB HRNBL-1 COJEC IND COURSE A | 100909480 |
| 160015545 | 160017981 | 1.62 | 85.6 | Curative (C) | 2017-03-19 | 2017-03-25 | EW EuroEwing 2012 Arm B VDC | 01 | Y | FLUOROURACIL + IRINOTECAN | 101403798 |
| 160015547 | 160017982 | 1.69 | 123.15 | null | 2019-01-30 | 2019-03-19 | ETOPOSIDE | null | null | PEMBROLIZUMAB | 101260596 |
| 160015570 | 160017983 | 1.69 | 15 | null | 2018-12-09 | 2018-12-23 | ATEZOLIZUMAB + BEVACIZUMAB | 02 | null | BLEOMYCIN | 100897573 |
| 160015593 | 160017984 | 1.5 | 114.6 | Curative (C) | 2019-02-09 | 2019-03-09 | NB HRNBL-1 BUMEL MAT | 02 | null | IRINOTECAN + CISPLATIN + MITOMYCIN | 100812647 |
| 160015595 | 160017985 | 0 | 98.2 | null | 2017-12-25 | 2018-05-20 | NB BEACON Dinutuximab, Temozolomide and Topotecan | 01 | null | IFOSFAMIDE | 100668641 |
| 160015600 | 160017986 | 0 | 53.7 | Curative (C) | 2021-05-06 | 2021-05-19 | null | 02 | N | RMS 2005 TRIAL | 101463599 |
| 160015618 | 160017987 | 1.56 | 11.5 | Palliative (P) | 2021-03-27 | 2021-04-08 | Ifosfamide | 02 | N | NAB-PACLITAXEL | 101108126 |
| 160015623 | 160017988 | 1.87 | 16.4 | null | 2018-12-31 | 2019-01-04 | Etoposide oral | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101534230 |
| 160015651 | 160017990 | 0 | 59.8 | null | 2020-05-25 | 2020-06-15 | ETOP 13-18 BEAT-meso Trial | 02 | null | PEMBROLIZUMAB | 101700481 |
| 160015669 | 160017991 | 1.64 | 63 | null | 2017-03-05 | 2017-03-16 | EW EuroEwing 2012 Arm A VAI | 02 | null | NIRAPARIB | 101035218 |
| 160015678 | 160017992 | 1.78 | 68.6 | null | 2019-08-14 | 2019-10-23 | CVP R | null | null | EW EUROEWING 2012 ARM B VDC | 100269210 |
| 160015679 | 160017993 | 1.7 | 124.5 | Curative (C) | 2017-06-05 | 2017-07-07 | EW EuroEwing 2012 Arm B IE | N | N | VINCRISTINE | 100494943 |
| 160015684 | 160017994 | 1.7 | 24.9 | Palliative (P) | 2016-09-08 | 2018-02-27 | DACTINOMYCIN + CYCLO + VINCRISTINE | 01 | N | STS RHABDO RMS 2005 VIN CYCLO | 101515064 |
| 160015696 | 160017995 | 1.55 | 80.8 | Palliative (P) | 2020-07-15 | 2020-07-21 | Dinutuximab Beta | 02 | null | CARBOPLATIN + ETOPOSIDE | 100650157 |
| 160015700 | 160017996 | null | 62.4 | Palliative (P) | 2018-05-08 | 2018-05-29 | Etoposide oral | 02 | N | NB HRNBL | 100400047 |
| 160015703 | 160017997 | 0 | 81.6 | Curative (C) | 2016-12-03 | 2017-02-04 | GEMCITABINE | 02 | Y | METHOTREXATE HIGH DOSE | 100934751 |
| 160015710 | 160017998 | 1.69 | 69.6 | Palliative (P) | 2020-05-08 | 2020-06-09 | Topotecan IV 7 day | 02 | N | TAZEMETOSTAT | 100023699 |
| 160015721 | 160018000 | 1.72 | 66.7 | Palliative (P) | 2021-06-05 | 2021-06-12 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 01 | N | DACARBAZINE | 101287278 |